Form 990 for tax year 2023

Revenue

Part VIII, the statement of revenue.

• 1f · All other contributions, gifts and grants

  $30,976,388

• 1g · Noncash contributions included above

  $251,490

• 2a · Program service revenue: RESEARCH & CLINICAL TRIALS

  total $1,281,492 · related or exempt $1,281,492

• 3 · Investment income

  total $1,696,550 · excluded $1,696,550

• 5 · Royalties

  total $192 · related or exempt $192

• 7a · Gross sales of assets other than inventory

  securities $103,230,530

• 7b · Less cost or other basis and sales expenses

  securities $103,234,562

• 7c · Gain or loss

  securities -$4,032

• 7d · Net gain or loss

  total -$4,032 · excluded -$4,032

Functional expenses

Part IX, the statement of functional expenses.

• 1 · Grants to domestic organizations and governments

  total $7,276,387 · program services $7,276,387

• 3 · Grants to foreign organizations and individuals

  total $775,000 · program services $775,000

• 5 · Compensation of officers, directors and key employees

  total $3,680,642 · program services $2,538,092 · management and general $375,543 · fundraising $767,007

• 7 · Other salaries and wages

  total $6,405,349 · program services $4,416,994 · management and general $653,550 · fundraising $1,334,805

• 8 · Pension plan contributions

  total $177,382 · program services $122,319 · management and general $18,099 · fundraising $36,964

• 9 · Other employee benefits

  total $549,023 · program services $378,595 · management and general $56,018 · fundraising $114,410

• 10 · Payroll taxes

  total $709,567 · program services $489,302 · management and general $72,398 · fundraising $147,867

• 11a · Fees: management

  total $344,764 · program services $318,092 · management and general $2,182 · fundraising $24,490

• 11b · Fees: legal

  total $57,505 · program services $53,056 · management and general $364 · fundraising $4,085

• 11c · Fees: accounting

  total $60,000 · program services $55,358 · management and general $380 · fundraising $4,262

• 11g · Fees: other

  total $5,662,222 · program services $4,435,659 · management and general $116,454 · fundraising $1,110,109

• 12 · Advertising and promotion

  total $2,009,835 · program services $1,631,552 · management and general $12,722 · fundraising $365,561

• 13 · Office expenses

  total $1,897,212 · program services $1,364,508 · management and general $3,285 · fundraising $529,419

• 14 · Information technology

  total $1,991,345 · program services $1,837,287 · management and general $12,605 · fundraising $141,453

• 16 · Occupancy

  total $207,010 · program services $190,995 · management and general $1,310 · fundraising $14,705

• 17 · Travel

  total $669,418 · program services $375,653 · management and general $9,583 · fundraising $284,182

• 19 · Conferences, conventions and meetings

  total $670,588 · program services $19,692 · fundraising $650,896

• 22 · Depreciation, depletion and amortization

  total $762,057 · program services $717,480 · management and general $14,749 · fundraising $29,828

• 23 · Insurance

  total $183,372 · program services $169,186 · management and general $1,161 · fundraising $13,025

• 24a · Other expenses: CLINICAL TRIAL/RESEARCH

  total $7,270,131 · program services $7,270,131

• 24b · Other expenses: TISSUE BANKING

  total $532,020 · program services $532,020

• 26 · Joint costs (an allocation of the lines above)

  total $303,228 · program services $151,177 · management and general $0 · fundraising $152,051

Balance sheet

Part X, book values.

• 1 · Cash, non-interest-bearing

  beginning of year $5,060,628 · end of year $1,373,960

• 2 · Savings and temporary cash investments

  beginning of year $13,092,430 · end of year $3,484,634

• 3 · Pledges and grants receivable

  beginning of year $5,229,372 · end of year $3,195,258

• 4 · Accounts receivable

  beginning of year $8,274,610 · end of year $3,739,397

• 9 · Prepaid expenses and deferred charges

  beginning of year $896,043 · end of year $715,352

• 10a · Land, buildings and equipment: cost or other basis

  $5,002,292

• 10b · Land, buildings and equipment: accumulated depreciation

  $2,364,594

• 10c · Land, buildings and equipment, net

  beginning of year $2,964,126 · end of year $2,637,698

• 11 · Investments: publicly traded securities

  beginning of year $41,091,535 · end of year $48,157,559

• 13 · Investments: program-related

  beginning of year $11,719,698 · end of year $16,363,985

• 15 · Other assets

  beginning of year $769,219 · end of year $559,789

• 17 · Accounts payable and accrued expenses

  beginning of year $15,173,286 · end of year $19,417,597

• 18 · Grants payable

  beginning of year $43,261 · end of year $980,000

• 19 · Deferred revenue

  beginning of year $9,131,077 · end of year $2,808,555

• 25 · Other liabilities

  beginning of year $1,060,123 · end of year $736,056

• 27 · Net assets without donor restrictions

  beginning of year $56,121,149 · end of year $53,786,450

• 28 · Net assets with donor restrictions

  beginning of year $7,568,765 · end of year $2,498,974

The filer's explanations (Part III)

PART I, LINE 4A

CHARLES VOLPE, DIRECTOR, PR & COMMUNICATIONS, RECEIVED A SEVERANCE PAYMENT OF $31,500 INCLUDED IN HIS 2023 FORM W-2.

PART I, LINE 7

INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2023, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2023 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

• MYELOMA INVESTMENT FUND LLC

  VENTURE PHILANTHROPY FUND · DE · income $1,588,166 · assets $21,345,357

  Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

• MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC

  FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH · CT · income $4,771,613 · assets $1,176,615

  Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC